NasdaqGS:STOKBiotechs
Stoke Therapeutics (STOK) Valuation After Strong 2025 Results And Progress In STK-002 And Zorevunersen
Stoke Therapeutics (STOK) is back in focus after reporting full year 2025 results, with sales of US$184.42 million and a sharply smaller net loss, alongside pipeline progress for STK-002 and zorevunersen.
See our latest analysis for Stoke Therapeutics.
At a share price of US$32.85, Stoke Therapeutics has given investors a very large 1 year total shareholder return of 355.62%. The 30 day share price return of a 9.78% decline suggests some recent momentum has cooled after a strong run helped by...